Home » Stocks » Compugen

Compugen Ltd. (CGEN)

Stock Price: $16.39 USD 0.06 (0.37%)
Updated Aug 10, 2020 4:00 PM EDT - Market closed
After-hours: $16.30 -0.09 (-0.55%) Aug 10, 5:55 PM

Stock Price Chart

Key Info

Market Cap 1.36B
Revenue (ttm) n/a
Net Income (ttm) -27.34M
Shares Out 82.86M
EPS (ttm) -0.37
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Aug 10, 2020
Last Price $16.39
Previous Close $16.33
Change ($) 0.06
Change (%) 0.37%
Day's Open 16.08
Day's Range 15.97 - 16.69
Day's Volume 1,050,736
52-Week Range 3.22 - 17.85

More Stats

Market Cap 1.36B
Enterprise Value 1.32B
Earnings Date (est) Nov 10, 2020
Ex-Dividend Date n/a
Shares Outstanding 82.86M
Float 165.12M
EPS (basic) -0.43
EPS (diluted) -0.37
FCF / Share -0.44
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 6.42M
Short Ratio 5.49
Short % of Float 11.05%
Beta 2.76
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio n/a
PB Ratio 10.53
Revenue n/a
Operating Income -28.88M
Net Income -27.34M
Free Cash Flow -27.66M
Net Cash 40.30M
Net Cash / Share 0.49
Gross Margin n/a
Operating Margin n/a
Profit Margin n/a
FCF Margin n/a
ROA -17.73%
ROE -32.65%
ROIC -1,349.30%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (7)

Buy 7
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

$20.14*
(22.88% upside)
Low
15.0
Current: $16.39
High
28.0
Target: 20.14
*Average 12-month price target from 7 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2019201820172016201520142013201220112010
Revenue-17.80-0.719.2812.373.550.24-1.12
Revenue Growth----92.33%-24.99%248.46%1366.53%---
Gross Profit-16.77-0.497.649.021.040.04-0.89
Operating Income-28.88-23.23-37.41-32.58-20.92-12.34-17.04-13.54-11.98-7.88
Net Income-27.34-22.60-37.07-31.51-20.16-11.09-14.08-13.63-12.00-7.20
Shares Outstanding63.6455.2851.1850.8650.4447.8138.8735.8434.2833.28
Earnings Per Share-0.43-0.41-0.72-0.62-0.40-0.26-0.36-0.38-0.35-0.22
Operating Cash Flow-27.89-13.29-30.66-19.82-25.61-11.15-6.44-10.85-9.25-4.28
Capital Expenditures0.23-0.16-0.39-2.60-3.12-1.90-0.33-1.01-0.10-0.02
Free Cash Flow-27.66-13.45-31.04-22.42-28.73-13.04-6.77-11.85-9.35-4.30
Cash & Equivalents43.8845.6830.4461.5381.8574.3851.4924.8822.4622.51
Total Debt3.58---------
Net Cash / Debt40.3045.6830.4461.5381.8574.3851.4924.8822.4622.51
Assets53.7653.1838.7571.1499.3111556.7128.9129.0836.46
Liabilities15.4415.949.457.629.418.8724.8211.249.508.17
Book Value38.3237.2429.3063.5289.9010631.8917.6719.5828.29
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Compugen Ltd.
Country Israel
Employees 61
CEO Anat Cohen-Dayag

Stock Information

Ticker Symbol CGEN
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: CGEN
IPO Date August 11, 2000

Description

Compugen Ltd., a clinical-stage therapeutic discovery and development company, engages in the research, development, and commercialization of therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; BAY 1905254, a therapeutic antibody targeting ILDR2, which is in Phase I clinical study in patients with solid tumors; and COM902, a therapeutic antibody targeting TIGIT. Its therapeutic pipeline also includes early-stage immuno-oncology programs focused primarily on myeloid targets. The company has collaboration agreement with Bayer Pharma AG for the research, development, and commercialization of antibody-based therapeutics for antibody-based therapeutics against the company's immune checkpoint regulators; Bristol-Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors; and Johns Hopkins School of Medicine to evaluate novel T cell and myeloid checkpoint targets. It has license agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products. Compugen Ltd. was incorporated in 1993 and is headquartered in Holon, Israel.